Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to
your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Email: portico-services@ucl.ac.uk
Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Intensive monitoring after resection of primary colorectal cancer advances diagnosis of liver and lung metastases but has not been shown to improve survival
-
Publication Type:Conference presentation
-
Publication Sub Type:Presentation
-
Authors:Treasure T, Brew-Graves C, Mokhles S, Williams N, Farewell V, Macbeth F, Russell C, Fiorentino F
-
Name of Conference:NCRI Cancer Conference
-
Conference place:Liverpool, UK
-
Conference start date:01/11/2015
-
Conference finish date:04/11/2015
-
Conference URL:
Abstract
Background
Resection of colorectal metastases in the liver and/or lung is undertaken with ‘curative intent’ but without supporting evidence from randomised controlled trials (RCTs). Policies of intensive monitoring after primary resection to detect asymptomatic metastases to increase opportunities for their resection have been the subject of RCTs.
Method
Systematic review and meta-analysis.
Results
Eight RCTs of intensive monitoring versus less intensive follow-up were found, reporting 3,988 randomised patients from 1994 to 2015. Monitoring methods changed over time. In 1994 CEA was regarded as intensive but later became standard as colonoscopy, CT and liver ultrasound were used with greater frequency in the intensive arms. Monitoring detected progressive disease 5-13 months (median nine) sooner than control in six studies reporting the lead time difference. Overall survival rates, around five years after randomisation, varied being 19%, 46%, 59%, 67%, 58%, 65%, 84% and 83% in successive trials. Because of the rising trend in survival of patients in RCTs over the passage of twenty years, data amalgamation was undertaken with caution. The trend may reflect earlier diagnosis of the primary cancer, variation in inclusion criteria in the RCTs, and/or improving results of treatment. In seven of eight RCTs there was no significant difference in survival. One study in 1998 reported better overall survival in the intensively monitored arm (73% vs 58%, N=207) associated with re-resection at the primary site but not related to metastasectomy. Increasing metastasectomy rates was the explicit intent of monitoring in two recent trials (2014/15) but more deaths were reported in the intensively monitored arms, without significant survival benefit.
Conclusion
Earlier detection leads to more diagnosed metastases and an increase in metastasectomy. Evidence from available RCTs does not demonstrate increased survival. We conclude that these policies have the potential to lead to overtreatment with major surgery without benefit.
› More search options
UCL Researchers